Technical / white paper
14-Apr-2010 -
With development times measured in years, increasing costs represent a major challenge confronting pharmaceutical and biotechnology companies. As a result, reducing time-to-market is an essential component in any business strategy, particularly when the end of patent protection is considered. One...
Technical / white paper
08-Jun-2011 -
With fewer blockbuster drugs in the pipeline, companies are on the lookout for an enduring solution to meet market challenges. These include rising process costs resulting from stricter quality control criteria, evolving technologies, which are becoming more complex and costly,...